Drug intelligence / Profile preview

DM1157

Development stage: Phase 1
Lead developer: DesignMedix
Modality: Small Molecules
Administration: Oral

Overview

DM1157 is a novel antimalarial drug candidate derived from chloroquine. It is designed to overcome drug resistance in malaria parasites by inhibiting the formation of hemozoin, which protects Plasmodium falciparum from heme toxicity. The drug also binds to the Plasmodium falciparum chloroquine resistance transporter (PfCRT), potentially impairing drug efflux and overcoming common resistance mechanisms. However, a Phase 1 clinical trial was halted early due to significant toxicity observed in healthy adult volunteers.

Targets

CALR (Calreticulin)PfFV heme (Plasmodium falciparum food vacuole heme)

Beyond the preview

Go deeper on DM1157.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DM1157.

Explore the full profile